Evidence map›Paper›PMID 27055875›Full record

ArticleLeukemia2016

Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.

Xavier Cheng-Hong Tsai, H-A Hou, J-L Tang, C-Y Liu, C-C Lin, W-C Chou, M-H Tseng, Y-C Chiang, Y-Y Kuo, M-C Liu and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 1 pooled it
11.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. TP53-Mutated Myelodysplasia and Acute Myeloid Leukemia.Mediterranean journal of hematology and infectious diseases · 2023
    Review
  20. Review

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 1 country.

Xavier Cheng-Hong TsaiDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
H-A HouDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
J-L TangDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
C-Y LiuBiostatistics Consulting Laboratory, School of Nursing, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.
C-C LinDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
W-C ChouDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
M-H TsengDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Y-C ChiangDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Y-Y KuoGraduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan.
M-C LiuDepartment of Pathology, National Taiwan University Hospital, Taipei, Taiwan.
C-W LiuDepartment of Pathology, National Taiwan University Hospital, Taipei, Taiwan.
L-I LinDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan.
W TsayDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
M YaoDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
C-C LiDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
S-Y HuangDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
B-S KoDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
S-C HsuDepartment of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan.
C-Y ChenDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
C-T LinDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
S-J WuDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
H-F TienDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
National Taiwan University Hospital · TWNational Taiwan University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A number of patient-specific and leukemia-associated factors are related to the poor outcome in older patients with acute myeloid leukemia (AML). However, comprehensive studies regarding the impact of genetic alterations in this group of patients are limited. In this study, we compared relevant mutations in 21 genes between AML patients aged 60 years or older and those younger and exposed their prognostic implications. Compared with the younger patients, the elderly had significantly higher incidences of PTPN11, NPM1, RUNX1, ASXL1, TET2, DNMT3A and TP53 mutations but a lower frequency of WT1 mutations. The older patients more frequently harbored one or more adverse genetic alterations. Multivariate analysis showed that DNMT3A and TP53 mutations were independent poor prognostic factors among the elderly, while NPM1 mutation in the absence of FLT3/ITD was an independent favorable prognostic factor. Furthermore, the status of mutations could well stratify older patients with intermediate-risk cytogenetics into three risk groups. In conclusion, older AML patients showed distinct genetic alterations from the younger group. Integration of cytogenetics and molecular mutations can better risk-stratify older AML patients. Development of novel therapies is needed to improve the outcome of older patients with poor prognosis under current treatment modalities.

Indexed as

MutationAgedAged, 80 and overAge FactorsCytogeneticsDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3AFemalefms-Like Tyrosine Kinase 3Genes, p53HumansLeukemia, Myeloid, AcuteMaleMiddle AgedMultivariate AnalysisNuclear ProteinsDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, humanFLT3 protein, humanfms-Like Tyrosine Kinase 3NPM1 protein, humanNuclear ProteinsNucleophosmin

Identifiers

PMID27055875
OpenAlexW2301134026

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.